News from pharmacyclics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Mar 19, 2015, 09:00 ET

New ibrutinib (IMBRUVICA®) Data to be Presented at American Association for Cancer Research (AACR) Meeting

  Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA®) will be...

Feb 27, 2015, 14:45 ET

Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that longer-term toxicology studies for its newly developed Bruton's tyrosine kinase (BTK)...

Feb 27, 2015, 14:30 ET

In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody

Pharmacyclics, Inc. (NASDAQ: PCYC) today highlighted findings from a pre-clinical study published in the Proceedings of the National Academy of...

Feb 18, 2015, 16:01 ET

Pharmacyclics Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Updates

 Pharmacyclics, Inc. (the "Company") (NASDAQ: PCYC) today reported financial results for the quarter and year ended December 31, 2014, as well...

Feb 17, 2015, 09:00 ET

IMBRUVICA® (ibrutinib) Treatment Shows Efficacy and Tolerability in Heavily Treated Chronic Lymphocytic Leukemia Patients Following Allogeneic Stem Cell Transplant

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that treatment with IMBRUVICA® (ibrutinib) was associated with an 88% overall response...

Feb 12, 2015, 10:40 ET

Pharmacyclics Announces Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results

  Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it will hold a conference call and audio webcast to discuss its financial results for...

Jan 29, 2015, 11:43 ET

U.S. FDA Approves IMBRUVICA® (ibrutinib) for Treatment of Waldenstrom's macroglobulinemia (WM)

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has granted single-agent IMBRUVICA®...

Jan 12, 2015, 17:45 ET

Pharmacyclics Announces Preliminary 2014 U.S. Net Product Revenue Results and 2015 U.S. Net Product Revenue Outlook

 Pharmacyclics, Inc. (NASDAQ: PCYC) today provided its preliminary unaudited 2014 U.S. net product revenue results and 2015 U.S. net product...

Jan 05, 2015, 09:00 ET

IMBRUVICA® (ibrutinib) Data Demonstrates Efficacy in Previously Untreated and Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that treatment with single-agent IMBRUVICA®...

Dec 22, 2014, 09:00 ET

Pharmacyclics Announces Update on IMBRUVICA® (ibrutinib) Waldenstrom's macroglobulinemia (WM) Submission

 Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that the U.S Food and Drug Administration (FDA) has provided a Prescription Drug User Fee...

Dec 12, 2014, 09:00 ET

Pharmacyclics Named 2014 Outstanding Company by BayBio

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has been awarded BayBio's 2014 Pantheon DiNA™ Award for Outstanding Company...

Dec 09, 2014, 09:00 ET

IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy

New IMBRUVICA® (ibrutinib) Phase II data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today demonstrates its potential utility as a...

Dec 09, 2014, 09:00 ET

IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in Mantle Cell Lymphoma

 New, 27-month IMBRUVICA® (ibrutinib) median follow-up data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today support the use of...

Dec 09, 2014, 09:00 ET

Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL)

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced new, longer term data in IMBRUVICA® (ibrutinib) patients with relapsed/refractory chronic...

Dec 08, 2014, 21:30 ET

IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in Mantle Cell Lymphoma

 New, 27-month IMBRUVICA® (ibrutinib) median follow-up data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today support the use of...

Dec 08, 2014, 21:02 ET

Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL)

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced new, longer term data in IMBRUVICA® (ibrutinib) patients with relapsed/refractory chronic...

Dec 08, 2014, 20:45 ET

IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy

New IMBRUVICA® (ibrutinib) Phase II data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today demonstrates its potential utility as a...

Dec 06, 2014, 15:01 ET

IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma

New IMBRUVICA® (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc. (NASDAQ: PCYC) during the 56th American Society...

Dec 05, 2014, 09:00 ET

Pharmacyclics Announces Launch of informCLL™ Registry for Chronic Lymphocytic Leukemia (CLL) Patients

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced the launch of informCLL™, a large, observational, prospective registry that will explore...